{"abstract":"The National Heart, Lung, and Blood Institute (NHLBI), an institute of the National Institutes of Health; an agency within the Department of Health and Human Services, is contemplating the grant of an exclusive patent license to commercialize the invention(s) embodied in the intellectual property estate stated in the Summary Information section of this notice to Corvidia Therapeutics Inc. (Corvidia) located in Waltham, MA and incorporated under the laws of Delaware.","action":"Notice.","agencies":[{"raw_name":"DEPARTMENT OF HEALTH AND HUMAN SERVICES","name":"Health and Human Services Department","id":221,"url":"https://www.federalregister.gov/agencies/health-and-human-services-department","json_url":"https://www.federalregister.gov/api/v1/agencies/221","parent_id":null,"slug":"health-and-human-services-department"},{"raw_name":"National Institutes of Health","name":"National Institutes of Health","id":353,"url":"https://www.federalregister.gov/agencies/national-institutes-of-health","json_url":"https://www.federalregister.gov/api/v1/agencies/353","parent_id":221,"slug":"national-institutes-of-health"}],"body_html_url":"https://www.federalregister.gov/documents/full_text/html/2017/04/04/2017-06546.html","cfr_references":[],"citation":"82 FR 16405","comment_url":null,"comments_close_on":"2017-04-19","correction_of":null,"corrections":[],"dates":"Only written comments and/or applications for a license which are received by the NHLBI Office of Technology Transfer and Development on or before April 19, 2017 will be considered.","disposition_notes":null,"docket_ids":[],"dockets":[],"document_number":"2017-06546","effective_on":null,"end_page":16406,"executive_order_notes":null,"executive_order_number":null,"full_text_xml_url":"https://www.federalregister.gov/documents/full_text/xml/2017/04/04/2017-06546.xml","html_url":"https://www.federalregister.gov/documents/2017/04/04/2017-06546/prospective-grant-of-exclusive-patent-license-development-and-commercialization-of-peptides","images":{},"images_metadata":{},"json_url":"https://www.federalregister.gov/api/v1/documents/2017-06546?publication_date=2017-04-04","mods_url":"https://www.govinfo.gov/metadata/granule/FR-2017-04-04/2017-06546/mods.xml","not_received_for_publication":null,"page_length":2,"page_views":{"count":104,"last_updated":"2026-08-24 00:15:06 -0400"},"pdf_url":"https://www.govinfo.gov/content/pkg/FR-2017-04-04/pdf/2017-06546.pdf","presidential_document_number":null,"proclamation_number":null,"public_inspection_pdf_url":"https://public-inspection.federalregister.gov/2017-06546.pdf?1491223525","publication_date":"2017-04-04","raw_text_url":"https://www.federalregister.gov/documents/full_text/text/2017/04/04/2017-06546.txt","regulation_id_number_info":{},"regulation_id_numbers":[],"regulations_dot_gov_info":{"checked_regulationsdotgov_at":"2023-03-01T00:17:01Z"},"regulations_dot_gov_url":null,"significant":null,"signing_date":null,"start_page":16405,"subtype":null,"title":"Prospective Grant of Exclusive Patent License: Development and Commercialization of Peptides Promoting Lipid Efflux for the Treatment of Hypertriglyceridemia, With or Without Concomitant Metabolic Syndrome","toc_doc":"Development and Commercialization of Peptides Promoting Lipid Efflux for Treatment of Hypertriglyceridemia, With or Without Concomitant Metabolic Syndrome","toc_subject":"Prospective Grant of Exclusive Patent Licenses:","topics":[],"type":"Notice","volume":82}